XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
XOMA , a biotech royalty aggregator listed on NASDAQ under the symbol 'XOMA', announced its participation in the H.C. Wainwright 2nd Annual Bioconnect Investor Conference. The event will take place at NASDAQ in New York on May 20, 2024.
CEO Owen Hughes and CIO Brad Sitko will represent XOMA in a fireside chat scheduled for 11:00 AM ET. The presentation can be accessed online via a provided link, and replays will be available on XOMA's investor relations website for 90 days post-event.
- Participation in the H.C. Wainwright 2nd Annual Bioconnect Investor Conference increases XOMA's visibility.
- Featuring key executives, Owen Hughes and Brad Sitko, provides investors with direct insights from top leadership.
- Access to the presentation and its replay could attract more investors and analysts.
- No specific financial or clinical updates were provided in the announcement.
- The event participation alone may not significantly impact stock performance without substantial news or data.
EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ being held on May 20, 2024, in New York, NY.
Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will be featured in a fireside chat taking place at 11:00 AM ET. The presentation can be accessed at https://bit.ly/4aQ74Y8.
XOMA’s presentations can also be accessed by visiting the investor relations section of the Company’s website at www.xoma.com. A replay of each presentation will be available and archived on the site for 90 days after the event.
About XOMA Corporation
XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com.
| XOMA Investor Contact | XOMA Media Contact |
| Juliane Snowden | Kathy Vincent |
| XOMA Corporation | KV Consulting & Management |
| +1 646-438-9754 | +1 310-403-8951 |
| juliane.snowden@xoma.com | kathy@kathyvincent.com |
FAQ
What event is XOMA participating in on May 20, 2024?
Who from XOMA will be presenting at the H.C. Wainwright Bioconnect Investor Conference?
How can I access XOMA's presentation at the Bioconnect Investor Conference?
Will there be a replay available for XOMA's presentation at the conference?
What is the stock symbol for XOMA ?
